Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Braz. j. infect. dis ; 11(1): 174-175, Feb. 2007.
Article in English | LILACS | ID: lil-454700

ABSTRACT

Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m², per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.


Subject(s)
Aged , Female , Humans , Antibodies, Monoclonal/therapeutic use , Cryoglobulinemia/drug therapy , Immunologic Factors/therapeutic use , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , Cryoglobulinemia/chemically induced , Hepatitis C/drug therapy , Interferon-alpha , Polyethylene Glycols/adverse effects , Polyethylene Glycols/therapeutic use , Ribavirin/adverse effects , Ribavirin/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL